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Abstract N-Glycanase 1 (NGLY1) is a cytoplasmic deglycosylating enzyme. Loss-of-function
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mutations in the NGLY1 gene cause NGLY1 deficiency, which is characterized by developmental
delay, seizures, and a lack of sweat and tears. To model the phenotypic variability observed among
patients, we crossed a Drosophila model of NGLY1 deficiency onto a panel of genetically diverse
strains. The resulting progeny showed a phenotypic spectrum from 0 to 100% lethality. Association
analysis on the lethality phenotype, as well as an evolutionary rate covariation analysis, generated
lists of modifying genes, providing insight into NGLY1 function and disease. The top association hit
was Ncc69 (human NKCC1/2), a conserved ion transporter. Analyses in NGLY1-/- mouse cells
demonstrated that NKCC1 has an altered average molecular weight and reduced function. The
misregulation of this ion transporter may explain the observed defects in secretory epithelium
function in NGLY1 deficiency patients.

†

These authors contributed
equally to this work

Competing interests: The
authors declare that no
competing interests exist.
Funding: See page 17
Received: 14 April 2020
Accepted: 12 December 2020
Published: 14 December 2020
Reviewing editor: Hugo J
Bellen, Baylor College of
Medicine, United States
Copyright Talsness et al. This
article is distributed under the
terms of the Creative Commons
Attribution License, which
permits unrestricted use and
redistribution provided that the
original author and source are
credited.

Introduction
NGLY1 deficiency (OMIM 615273) is a rare, autosomal recessive disorder caused by loss-of-function
mutations in the NGLY1 gene. Patients with NGLY1 deficiency have a variety of symptoms, including
developmental delay, seizures, liver dysfunction, central and peripheral nervous system abnormalities, sweat gland abnormalities, and a lack of tears (alacrima) (Enns et al., 2014; Lam et al., 2017).
While the first NGLY1 deficiency patient was only recently identified (Need et al., 2012), there have
been rapid research advances thanks to the support of two patient organizations (NGLY1.org and
Grace Science Foundation). Even though a great deal has been learned about the genetic disorder
in a short amount of time, there are currently no cures or approved treatments for NGLY1
deficiency.
The NGLY1 gene encodes the N-Glycanase protein (NGLY1). NGLY1 functions as part of the
Endoplasmic Reticulum (ER) Associated Degradation (ERAD) pathway as evidenced by its association
with other ERAD components (Katiyar et al., 2005; McNeill et al., 2004; Park et al., 2001). The
ERAD pathway retrotranslocates misfolded proteins from the ER lumen to the cytoplasm where they
are degraded by the proteasome (reviewed in Qi et al., 2017). NGLY1 is localized to the cytoplasm
where it is thought to remove N-linked glycans from misfolded proteins prior to their degradation
(Hirsch et al., 2003). Recent evidence suggests that this deglycosylation is required for retrotranslocation for at least some protein substrates (Galeone et al., 2020). Nevertheless, it remains unclear
whether NGLY1 is required to deglycosylate all misfolded proteins, or just a subset, or if it is

Talsness, Owings, et al. eLife 2020;9:e57831. DOI: https://doi.org/10.7554/eLife.57831

1 of 22

Research article

Cell Biology Genetics and Genomics

necessary for protein degradation at all. It has been shown that model substrates can be degraded
regardless of glycosylation state (Hirsch et al., 2003; Kario et al., 2008). While a recent report
showed that ER stress markers were increased in NGLY1 -/- MEFs (Galeone et al., 2020), other
experiments such as RNAi knockdown (KD) of NGLY1 in Drosophila (Owings et al., 2018) and loss
of NGLY1 function in mouse, rat, and human cells (Asahina et al., 2020; Mueller et al., 2020;
Tambe et al., 2019) have shown no evidence of ER stress. ER stress is often observed when there
are mutations in proteins that are necessary for ERAD due to the accumulation of misfolded proteins
in the ER. It may be that NGLY1 is not necessary for ERAD, or it is involved in a non-canonical ERAD
function, or it may be deglycosylating cytoplasmic proteins for an entirely different purpose. These
hypothesized functions are not mutually exclusive.
NGLY1 has been shown to deglycosylate various exogenous model substrates such as TCR-a
(Hirsch et al., 2003) and RNaseB (Kario et al., 2008). To identify endogenous substrates several
mass spectrometry experiments have been performed (Fujihira et al., 2017; Hosomi et al., 2016;
Maynard et al., 2020; Zolekar et al., 2018). Yet, the first high-confidence substrate of NGLY1
deglycosylation, NRF1 (gene: NFE2L1), was discovered in a Caenorhabditis elegans genetic screen
(Lehrbach and Ruvkun, 2016). NRF1 mediates a proteasome ‘bounce-back’ response. NRF1 is constitutively degraded by the proteasome through the ERAD pathway, until the proteasome is inhibited or overwhelmed by protein load. During this proteasome stress, NRF1 accumulates and is
deglycosylated by NGLY1 (Tomlin et al., 2017). Rather than targeting the protein for degradation,
the deglycosylation activates NRF1 by converting asparagine to aspartic acid residues
(Lehrbach et al., 2019). NRF1 can then be imported into the nucleus to act as a transcription factor
for proteasome subunits. The lack of NRF1 activation in NGLY1-deficient patients likely explains
some of the disorder’s symptoms such as motor dysfunction (Kobayashi et al., 2011) and cognitive
deficits (Lee et al., 2011). Recently, it was found that the protein BMP4 is deglycosylated by NGLY1
when overexpressed in either Drosophila or mammalian cells (Galeone et al., 2020). BMP4 is a signaling molecule and could explain several of the developmental symptoms of NGLY1 deficiency.
However, not all symptoms can be explained by these two targets and therefore there is a pressing
need to identify and validate more substrates of NGLY1 deglycosylation.
In addition to discovering new NGLY1 targets, there is a need to understand how background
genetic variants affect the number and severity of symptoms in patients. While the majority of
patients harbor two complete loss-of-function mutations in NGLY1 (He et al., 2015), there are many
symptoms such as seizures and scoliosis that are only reported in a subset of the patients
(Enns et al., 2014). All patients experience developmental delay, but it ranges from slightly below
average IQ to completely non-verbal (Lam et al., 2017). This variability based on background genetics was also observed in the lab when an NGLY1 deficiency mouse model was crossed onto an outbred mouse strain which partially rescued the lethality of the model (Fujihira et al., 2017). In order
to identify components of the genetic background that affect the range of symptoms and severity of
disease, we have utilized a collection of genetically diverse Drosophila strains known as the Drosophila Genetic Reference Panel (DGRP) (Mackay et al., 2012). By crossing a fly model of NGLY1 deficiency onto the panel, we recapitulated the variable phenotype seen in the human population. Here,
we report the results of this cross and a list of candidate modifier genes derived from the genomewide association (GWA) of the cross. To contextualize the candidate modifier list, we also performed
an evolutionary rate covariation (ERC) analysis to identify genes that are co-evolving with NGLY1.
Together these two genetic analyses have generated a list of genes that (1) may explain some of the
variation seen between NGLY1 patients, (2) may encode proteins that physically interact with NGLY1
in ERAD or other cellular processes, and (3) may be direct deglycosylation targets of NGLY1. The
top candidate modifier gene from the GWA is NKCC1, a conserved Na/K/Cl ion co-transporter. We
found that NKCC1 modifies multiple phenotypes in Drosophila, and in NGLY1 -/- mammalian cells,
NKCC1 displays abnormal average molecular weight and has reduced activity. The misregulation of
NKCC1 likely explains several prominent secretory epithelium-related phenotypes observed in
NGLY1 deficiency patients.
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Results
Variation in lethality associated with NGLY1 deficiency
We crossed a fly model of NGLY1 deficiency (Pngl in flies, hereon referred to as NGLY1) onto 163
strains of the DGRP in order to assess the effect of natural variation on loss of NGLY1 function. We
have previously validated this NGLY1 deficiency model where an NGLY1 RNAi reduces NGLY1 transcript by >95% when driven by the ubiquitous Tubulin-GAL4 driver transgene (Tubulin > NGLY1
RNAi) (Owings et al., 2018). In order to cross a ubiquitously expressed NGLY1RNAi onto the DGRP
strains in a single cross, we needed to overcome the lethality associated with loss of NGLY1
(Owings et al., 2018). To do this, a Tubulin-GAL80 transgene, which represses the effect of GAL4,
was crossed onto the Tubulin > NGLY1 RNAi background, such that RNAi is not expressed and flies
from this parent strain are healthy and viable (Figure 1A). This donor strain was crossed to each
DGRP strain to generate F1 flies that have both ubiquitous KD of NGLY1 and 50% of their genome
from each respective DGRP strain (Figure 1B). In this way, analyzing the F1 progeny was a direct
measurement of the dominant effect of the DGRP genetic variants on the NGLY1 KD phenotype.
The phenotypic outcome used for this screen was adult survival through eclosion. We simply
scored all adults emerging from each cross in the four balancer categories: CyO, Sb, double balanced, or no balancers, with the no balancer flies being the NGLY1 KD. If no lethality is present,
Mendelian segregation should produce the expected 1:1:1:1 ratio of the genotypes. Given that
there is a very low level of lethality associated with each balancer, the largest balancer class is the
closest to the expected, and was used to calculate the ratio of lethality for NGLY1 KD. Results of the
screen reveal that survival to adulthood was strongly influenced by DGRP genetic background
(Figure 1B; Supplementary file 1), with proportion of surviving flies ranging from 0.0 to 0.967. Survival to adulthood was not correlated with efficiency of RNAi, as there was no difference in KD efficiency in flies from either end of the phenotypic distribution (low surviving: 92.0% ± 3.7; high
surviving: 94.8% ± 3.7; p=0.4). There was no correlation between proportion of surviving flies and
the absolute number of flies in the balancer class (R2 = 0.02; p=0.14), indicating that the ratio is not
driven by the number of the balancer control flies.

Genome-wide association
We hypothesized that the observed variable survival to adulthood in NGLY1 KD flies was due to the
underlying genetic variation in the DGRP. Therefore, genome-wide association (GWA) analysis of the
fully sequenced DGRP was used to identify variants that associated with NGLY1 KD survival. We
used
a
linear
mixed
model
to
test
2,007,145
single-nucleotide
polymorphisms (SNPs; Supplementary file 2). We recognize that our study suffers from a multiple

Figure 1. Lethality phenotype of NGLY1 knockdown is highly modifiable by strain background. (A) Drosophila cross for NGLY1 knockdown in each
Drosophila genetic reference panel (DGRP) strain. (B) Proportion of NGLY1 knockdown flies surviving for each cross was calculated based on the
number eclosing compared to the expected number. Expected number was based on the largest control balancer class for each cross.
The online version of this article includes the following figure supplement(s) for figure 1:
Figure supplement 1. Ncc69 expression is not correlated with survival.
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testing problem, making it difficult to interpret the role of any single SNP identified. Instead, the
location of SNPs was used to identify candidate modifier genes. This type of approach has worked
well in the past for other disease models (Ahlers et al., 2019; Chow et al., 2013a; Chow et al.,
2013b; Lavoy et al., 2018; Palu et al., 2019) and provides an unbiased list of candidate genes that
can be functionally tested for interactions with NGLY1.
At a nominal p-value of p<10 5, 125 variants are associated with survival to adulthood. Of these
125 variants, 21 fall outside of a gene region (+/- 1 kb from the 5’ or 3’ UTRs) (Supplementary file
3). The remaining 104 variants map to 61 protein coding candidate genes (Table 1). Eighty-five of
these 104 variants are in noncoding regions (UTRs, introns, or upstream or downstream) and 19 are
in coding regions. Of these 19, 12 are synonymous changes and 7 are nonsynonymous (exp, hiw,
CG30048, SP2353, CG31690, Hrd3, and blue). When multiple testing correction is applied to all the
variants, the top 12 remain significant. Nine of these SNPs reside in an intron of the Ncc69 gene. All
nine SNPs are in strong linkage disequilibrium with each other, which is quite unusual for the DGRP.
When we analyzed Ncc69 expression levels using previously published RNAseq data from the DGRP
(Everett et al., 2020), we found there was no correlation with survival (Figure 1—figure supplement 1).
Gene ontology (GO) enrichment analysis of the 61 candidate genes did not identify enrichment in
any biological process or molecular function. However, GO enrichment was identified for the cellular
component categories ‘cell periphery’ (GO:0071944; 19/61; q < 0.0016) and ‘plasma membrane’
(GO:0005886; 17/61; q < 0.004). At least 12/61 candidate genes are involved in protein homeostasis: three are involved in ERAD (CG8405, CG42383, and Hrd3), six are ER resident or membrane proteins (CG33012, CG30043, CG31690, CG4341, Hrd3, and CG8405), four are involved in
ubiquitination or the proteasome (hiw, blue, CG42383, and Hrd3), one regulates heatshock
responses (Hsromega), and one regulates N-linked glycosylation (sff).
Three of the identified ERAD genes already have known interactions with NGLY1. CG8405 is the
Drosophila ortholog of human TMEM259, which physically interacts with NGLY1 in co-immunoprecipitation experiments (Zhu et al., 2017). CG42383 is the Drosophila ortholog of human NSFL1C
(cofactor p47). NSFL1C and NGLY1 interact with the VCP/P97 AAA-ATPase complex involved in
delivering misfolded proteins from the ERAD complex to the proteasome for degradation
(Kondo et al., 1997; McNeill et al., 2004). Hrd3 is the Drosophila ortholog of SEL1L. SEL1L is a
component of the ERAD complex required for retrotranslocation of misfolded proteins from the ER
to the cytoplasm for degradation. Recently, the C. elegans orthologs of NGLY1 and SEL1L were
both identified as modifiers of NRF1 function (Lehrbach and Ruvkun, 2016). These candidate genes
are a proof-of-principle that this screen has identified functionally relevant modifiers.
The four candidate genes that encode ER resident proteins are particularly interesting. CG31690
and CG4341 are both Drosophila orthologs of human TMTC2, an ER transmembrane protein that
regulates calcium homeostasis. CG33012 and CG30043 are both Drosophila orthologs of human
ERMP1, an ER metalloprotease. It is striking that in both cases, both Drosophila orthologs of a single
human gene were identified as candidate modifiers, suggesting that the function of TMTC2 and
ERMP1 might be particularly important for NGLY1 lethality. It is not clear how these genes might
modify NGLY1 lethality, but their physical localization to the ER makes sense and suggests a possible
role in protein homeostasis as well.

Gene set enrichment analysis
The rank-order candidate modifiers identified in our GWA ignores the majority of the association
data by only considering one variant at a time, rather than all the variants associated with a particular
gene. Therefore, we performed a gene set enrichment analysis (GSEA), which assigns each variant to
the closest gene and generates a per gene metric for p-value enrichment (Palu et al., 2019;
Subramanian et al., 2005). Given a defined set of genes annotated with a certain GO function,
GSEA determines whether the members of that set are randomly distributed throughout the ranked
list or if they are found primarily at the top or bottom of that list. We identified 21 gene sets positively associated with the ranked gene list (5 genes;>0.25 enrichment score; p<0.05) (Figure 2;
Supplementary file 4). These data suggest that these GO categories are closely linked to NGLY1
activity and variation in individual genes in these categories contribute to the distribution of lethality
observed in our screen.
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Table 1. Candidate modifier genes identified from GWA.
Rank order of candidate genes was established based on the most significant associated SNP in the respective gene.
Rank order

Gene

FBgn

Human ortholog

Periphery/membrane

Proteostasis

1

exp

FBgn0033668

—

no

no

2

Ncc69

FBgn0036279

NKCC1/2

yes

no

3

CG5888

FBgn0028523

—

yes

no

4

CG16898

FBgn0034480

—

no

no

5

bru3

FBgn0264001

CELF2/3/4/5/6

no

no

6

CG31690

FBgn0051690

TMTC2

no

yes

7

CG7227

FBgn0031970

SCARB1

no

no

8

CR44997

FBgn0266348

—

no

no

9

rgn

FBgn0261258

Many

no

no

10

M6

FBgn0037092

GPM6A

yes

no

11

Rab26

FBgn0086913

RAB26

yes

yes

12

Obp56i

FBgn0043532

—

no

no

13

5-HT1A

FBgn0004168

HTR1A

yes

no

14

CG33012

FBgn0053012

ERMP1

no

yes

15

rst

FBgn0003285

—

yes

no

16

CR43926

FBgn0264547

—

no

no

17

CG7337

FBgn0031374

WDR62

no

no

18

hiw

FBgn0030600

MYCBP2

yes

yes

19

fid

FBgn0259146

TRMT9B

no

no

20

nmo

FBgn0011817

NLK

no

no

21

Sirup

FBgn0031971

SDHAF4

no

no

22

tst

FBgn0039117

SKIV2L

no

no

23

Mdr50

FBgn0010241

many

yes

no

24

Cpr49Aa

FBgn0050045

—

no

no

25

COX7C

FBgn0040773

COX7C

no

no

26

Eip63E

FBgn0005640

CDK14/15

yes

no

27

CG30048

FBgn0050048

PKD1

no

no

28

CG15040

FBgn0030940

—

no

no

29

SP2353

FBgn0034070

EGFLAM

no

no

30

Mf

FBgn0038294

—

no

no

31

ome

FBgn0259175

many

no

no

32

esn

FBgn0263934

PRICKLE1-3

no

no

33

haf

FBgn0261509

many

no

no

34

dally

FBgn0263930

GPC3/5

yes

no

35

robo2

FBgn0002543

ROBO1/2/3/4

no

no

36

Gyc32E

FBgn0010197

NPR1/2

yes

no

37

CG8170

FBgn0033365

many

no

no

38

CG8405

FBgn0034071

TMEM259

no

yes

39

scaf

FBgn0033033

—

yes

no

40

borr

FBgn0032105

CDCA8

yes

no

41

Syx7

FBgn0267849

STX7/12

yes

no

42

DIP-delta

FBgn0085420

many

yes

no

43

cv-c

FBgn0285955

DLC1

yes

no

Table 1 continued on next page
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Table 1 continued
Rank order

Gene

FBgn

Human ortholog

Periphery/membrane

Proteostasis

44

Snmp2

FBgn0035815

CD36/SCARB1

no

no

45

Mer

FBgn0086384

NF2

yes

no

46

sba

FBgn0016754

—

no

no

47

Hsromega

FBgn0001234

—

no

yes

48

CCAP-R

FBgn0039396

NPSR1

yes

no

49

Hrd3

FBgn0028475

SEL1L

no

yes

50

blue

FBgn0283709

NEURL4

no

yes

51

CG6262

FBgn0034121

TREH

no

no

52

CG45186

FBgn0266696

SVIL

no

no

53

Spn

FBgn0010905

PPP1R9A

yes

no

54

dnc

FBgn0000479

PDE4A/B/C/D

no

no

55

CG4374

FBgn0039078

many

no

no

56

sff

FBgn0036544

many

no

yes

57

CG42383

FBgn0259729

NSFL1C

no

yes

58

Dyb

FBgn0033739

DTNB

yes

no

59

CG34371

FBgn0085400

—

no

no

60

CG4341

FBgn0028481

TMTC2

no

yes

61

CG30043

FBgn0050043

ERMP1

no

yes

Some of the most significantly enriched categories such as nuclear transport, rRNA processing
and signal transduction are broad categories that could have wide reaching implications for NGLY1
function. These processes, however, are difficult to test and require long-term investigation, beyond
the scope of this study. Circadian rhythm, on the other hand, is a specific and testable category. The
enriched category for circadian rhythm function contains a number of genes that directly modulate
circadian rhythm, including, clock, period, timeless, and cycle. We hypothesized that if variation in
circadian rhythm function modifies lethality associated with loss of NGLY1 function then NGLY1
must affect the circadian rhythm. To test this, we knocked down NGLY1 in the LNv pacemaker neurons in the central nervous system using the Pdf-GAL4 driver (Renn et al., 1999) and assayed rhythmicity of locomotor activity in constant darkness over 8 days in Drosophila Activity Monitors (DAM).
Compared to Pdf-GAL4/+ and UAS-NGLY1RNAi controls, flies with NGLY1 KD exhibited a significantly longer period length (Figure 2—figure supplement 1), supporting the idea that NGLY1 function can affect sleep. Indeed it has been reported that patients with NGLY1 deficiency experience
disturbed sleep patterns (Enns et al., 2014; Lam et al., 2017).

Evolutionary rate covariation
Many of the GWA and GSEA results are intriguing, but appear far removed from the currently known
functions of NGLY1. We hypothesized that we could contextualize some of the gene and network
results by discovering which of them might be co-evolving with NGLY1. Therefore, we employed
evolutionary rate covariation (ERC) analysis (Wolfe and Clark, 2015). Gene pairs with high ERC values have correlated rates of substitution and are thought to function together in protein complexes
or related pathways. ERC analysis identified hundreds of protein-coding genes with integrated ERC
scores exceeding two with NGLY1 (column ‘sumnlogpvbest’ in Supplementary file 5). Of the 38
GWA candidates that have human orthologs, two were found in this group with elevated NGLY1
ERC values, CG4374 (many) and esn (PRICKLE1). While this overlap is not enriched above background, co-evolution suggests that these two genes might have a particularly important interaction
with NGLY1.
GO analysis was used to determine if there was enrichment in any biological pathways among
NGLY1 co-evolving genes. Among the top enriched pathways were ‘rRNA/ncRNA/ribosome
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Figure 2. Gene set enrichment analysis. Top significant ontological categories identified by GSEA. p-values are
indicated by red-to-blue gradient, with red the lowest p-values and blue the highest p-values. Gene number
identified in each category is indicated by the size of the circle.
The online version of this article includes the following figure supplement(s) for figure 2:
Figure supplement 1. NGLY1 knockdown causes circadian rhythm defect.

biogenesis/metabolism-related functions’ and ‘functions related to nuclear pore complex’. This is
particularly exciting as both processes overlap with the top GO enrichment categories observed in
the GSEA analysis, suggesting that the same functional categories that contribute to variation in
NGLY1-related lethality also appear to contain genes that co-evolve with NGLY1. The rRNA processing category (GO:0006364) contained six genes overlapping between the two analyses. This overlap
is higher than expected, given two equally sized random groups of genes (GSEA: 23 genes; ERC: 37
genes; p<2.610 12). Among other ncRNA-related enriched GO categories from the ERC analysis
are ncRNA metabolic process (GO:0034660), ncRNA processing (GO:0034470), tRNA metabolic process (GO:0006399), ribosome biogenesis (GO:0042254), and tRNA modification (GO:0006400). The
functions related to the nuclear pore included nuclear export (GO:0051168), nuclear pore organization (GO:0006999), nuclear transport (GO:0051169), and nuclear pore complex assembly
(GO:0051292). While there was no overlap between ERC and GSEA for exact nuclear pore function
categories, GSEA results were enriched for functions related to nuclear import (GO:0042306 and
GO:0006606). Together, these observations suggest previously unknown roles for NGLY1 in ncRNA
and nuclear pore functions.
NGLY1 deficiency is part of a larger category of disorders known as Congenital Disorders of Glycosylation (CDG), with NGLY1 being the only protein that actually deglycosylates substrates. There
are 151 known CDG genes. GO analysis of the ERC results identified enrichment of the GPI anchor
biosynthetic process, which contains several of these CDG genes, leading us to believe that other
CDG genes may have been ERC hits. However, the 151 CDG genes do not fall into one functional
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GO category, therefore, we manually curated the ERC list and identified 26 CDG genes that coevolve with NGLY1 (see color coding in Supplementary file 5). This represents a significant overlap
above what is expected by chance (p<7.610 10). In particular, 5 of the 21 genes involved in
N-linked glycosylation and 9 of the 29 genes involved in GPI-anchor biogenesis are co-evolving with
NGLY1. The remaining 10 genes are spread across the CDG functional spectrum. The identification
of a number of CDG genes that co-evolve with NGLY1, suggests that NGLY1 function might be
important to the broader glycosylation pathways.

Genetic interaction between NGLY1 and Ncc69 in Drosophila
While these genetic analyses revealed many promising modifying and co-evolving genes which
should be investigated, we began by investigating Ncc69 because it was the top hit with a human
ortholog in our GWA analysis. Further, Ncc69 is a glycoprotein, making it a potential target of
NGLY1 deglycosylation. Ncc69 has two mammalian orthologs, NKCC1 and NKCC2. While Ncc69 is
ubiquitously expressed in Drosophila, NKCC1 (gene: SLC12A2) is highly expressed in secretory epithelia and NKCC2 (gene: SLC12A1) is primarily expressed in the kidney (Delpire and Gagnon,
2018). In all cases, the protein is a 12-pass transmembrane cation-chloride co-transporter that brings
Na+, K+, and Cl- into the cell (Delpire and Gagnon, 2018). Mutations in NKCC2 are known to cause
type I Bartter syndrome (Simon and Lifton, 1996) and a recent clinical report shows homozygous
loss-of-function mutations in NKCC1 cause the novel disease Kilquist syndrome (Macnamara et al.,
2019).
To validate the genetic interaction observed between NGLY1 and Ncc69 in the GWA, we generated ubiquitous double knockdown (DKD) Drosophila and scored offspring that survived to eclosion
(Figure 3A). The fraction of KD flies was calculated from observed offspring of the balancer phenotype. NGLY1 KD caused a decrease in survival to ~25%, in accordance with our previous report of
this RNAi line (Owings et al., 2018). Ncc69 KD did not cause any significant decrease in survival
(c2=1.002, p=0.3168), as previously reported (Leiserson et al., 2011). The DKD, however, caused
complete lethality. This synthetic lethality confirms Ncc69 as a hit from the NGLY1 modifier screen.
KD of cation-chloride cotransporters in glia has been shown previously to cause seizures in Drosophila (Rusan et al., 2014), and we wanted to test whether this phenotype could be modified by
NGLY1 KD. We performed single and double knockdowns of NGLY1 and Ncc69 in glial cells using
the repo-GAL4 driver. This Ncc69 RNAi line is the same as the one described above. Drosophila

Figure 3. NGLY1 and Ncc69 interact genetically in Drosophila. (A) Proportion of flies surviving to eclosion in ubiquitous knockdowns. NGLY1
knockdown (KD) are UAS-PnglRNAi/+; Tubulin-GAL4/+. Ncc69 KD are UAS-Ncc69RNAi/+; Tubulin-GAL4/+. NGLY1 Ncc69 double knockdown (DKD) are
UAS-PnglRNAi/+ UAS-Ncc69RNAi/Tubulin-GAL4/+. Four separate matings were performed for each cross with at least 40 offspring generated for the
balancer control for each. Fraction surviving is calculated compared to balancer offspring. Chi-square analysis was performed for the total number of
flies compared to expected Mendelian numbers. NGLY1 KD c2 = 109.7, p<0.0001; Ncc69 KD c2 = 1.002, p=0.3168, and NGLY1 Ncc69 DKD c2 = 186,
p<0.0001. (B) Bang sensitivity assay to assess seizures in glial knockdown flies. WT flies are attP2 and attP40. NGLY1 KD are UAS-PnglRNAi/+; repoGAL4/+. Ncc69 KD are UAS-Ncc69RNAi/+; repo-GAL4/+. NGLY1 Ncc69 DKD are UAS-PnglRNAi/+; UAS-Ncc69RNAi/ repo-GAL4. For each genotype, at
least 45 4- to 7-day-old females were used to calculate the percent seizing at a given time after vortexing. Repeated measures ANOVA
p-value=0.000176.
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were assessed for seizure phenotype using the bang sensitivity assay (Figure 3B). Control, wild-type
flies show immediate recovery, as expected. In NGLY1 KD flies, ~30% showed severe seizures in the
form of complete immobility 5 s following vortex. However, by 10 s following vortex, NGLY1 KD flies
were completely recovered. This is the first report of seizure phenotype in any NGLY1 deficiency
model, mimicking what is observed in patients. Ncc69 KD flies showed severe seizures with 75%
seizing at 5 s following vortex, in line with previous reports (Rusan et al., 2014). In the DKD, there
was a partial rescue of the severe Ncc69 phenotype. At all time-points between 5 and 60 s, the DKD
flies showed an intermediate phenotype relative to NGLY1 and Ncc69 single KDs, confirming a
genetic interaction between NGLY1 and Ncc69.

Functional analysis of NKCC1 in NGLY1 null MEFs
To understand the cell biology behind the genetic interaction that was observed in Drosophila, we
utilized NGLY1 knockout (-/-) mouse embryonic fibroblasts (MEFs) (jax.org/strain/027060). Fibroblasts should only express the ubiquitous ortholog, NKCC1 (Haas and Forbush, 1998). When the
membrane fraction of NGLY1 -/- MEFs was analyzed by immunoblot for NKCC1 there was a noticeable shift in the average molecular weight of the band compared to wildtype, control cells (+/+)
(Figure 4A). Using the molecular weight marker to calculate the size of the proteins (un-cropped
blot in Figure 4—figure supplement 1), the upper limits of the bands were ~170 kDa for both +/+
and -/- cells (Figure 4B). The lower limit of the bands, however, were ~140 kDa for +/+ cells
and ~150 kDa for the -/- cells (Figure 4C).
To determine if a glycosylation event might be responsible for this size difference, cell lysates
were treated with deglycosylating enzymes (Figure 4D). PNGase F removes all N-linked glycans and
this treatment caused a large decrease in the molecular weight, to ~125 kDa in NKCC1 proteins
from both NGLY1 +/+ and -/- cells. The expected weight of mouse NKCC1 without any post-translational modifications is 130 kDa indicating that all post-translational modifications are likely N-linked

Figure 4. Endogenous NKCC1 is altered in NGLY1-deficient MEFs. (A) Control (+/+) and NGLY1 null (-/-) MEFs were grown to confluency and then
lysed to isolate the membrane and cytoplasmic fractions. Three separate membrane lysates for both genotypes were analyzed by immunoblotting for
NKCC1 compared to a molecular weight marker (MWM). Blot was used for molecular weight calculations of the upper-most limit (see un-cropped blot
in Figure 4—figure supplement 1) (B) And the lower-most limit (C) of the protein band. Red bar represents the mean. Two-tailed t-test was used to
calculate p-values. (D) Membrane lysates from MEFs were treated with N-Glycosidase F (PNGase F), O-Glycosidase (O-Gly), or Endoglycosidase H
(Endo H) for 1 hr then analyzed by immunoblot. Control (C)Samples were treated in all the same conditions but without the added enzyme. (E) MEFs
were treated with 500 nM bortezomib (Bz) or equal volume of vehicle control (DMSO) for 4 hr then lysed to collect membrane and cytoplasmic
fractions. Lysates were analyzed by immunoblotting for NKCC1. NRF1 was analyzed as a positive control of proteasome inhibition. Dark band at about
140 kDa in both (A), (D), and (E) is believed to be non-specific.
The online version of this article includes the following figure supplement(s) for figure 4:
Figure supplement 1. Full western blot of NKCC1 in NGLY1 +/+ and -/- MEFs.
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glycans. This is in accordance with the prediction of two canonical N-linked glycosylation sites
(Payne et al., 1995). The fact that there is no difference in molecular weight between the +/+ and
-/- after treatment indicates the difference observed in the untreated state was eliminated by the
PNGase enzyme. Treatment with O-Glycosidase had no effect on the molecular weight of the band
in either the +/+ or -/- lysates. Although O-Glycosidase does not cleave every type of O-linked glycan, these results coupled with the PNGase results indicate there are likely no O-linked glycans on
NKCC1. Finally, to determine the maturation state of the N-linked glycans Endoglycosidase H was
used. No change in molecular weight was seen, indicating the N-linked glycans are no longer in the
high-mannose state in both the +/+ and -/- cells.
The most well-studied substrate of NGLY1, NRF1, is degraded by the proteasome under normal
conditions, and only when the proteasome is stressed or inhibited does NRF1 become active.
Indeed, NGLY1 is thought to act in the ERAD pathway and therefore all its substrates may be regulated in some way by proteasomal degradation. To test if NKCC1 abundance is affected by the proteasome, MEFs were treated with the proteasome inhibitor bortezomib (Bz). As expected, there was
an increase in NRF1 abundance during proteasome inhibition (Figure 4E). However, there was no
noticeable increase in NKCC1 protein for either the +/+ or -/- MEFs, indicating proteasomal degradation is not a major regulator of NKCC1.
Given the altered glycosylation state of NKCC1 observed in NGLY1 -/- MEFs, we wanted to
determine the functionality of NKCC1 in these cells. Previous reports have shown that inhibiting
N-linked glycosylation can decrease functionality for both NKCC1 (Singh et al., 2015) and for
NKCC2 (Paredes et al., 2006), and therefore, we hypothesized that the misglycosylation might also
decrease function. The NKCC proteins and the Na+/K+-ATPase can both transport Rb+ in place of
K+, so we incubated cells with radioactive 86Rb and measured cellular uptake. Cells were assayed in
the presence or absence of 10 mM bumetanide, an NKCC inhibitor, or 100 mM ouabain, a Na+/K+ATPase inhibitor, as compared to vehicle control. When the ouabain-sensitive and bumetanide-sensitive activities were summed, they accounted for all of the 86Rb flux observed (Figure 5—figure supplement 1). We found that bumetanide-sensitive 86Rb flux, but not ouabain-sensitive flux, was
impaired by ~50% in the -/- MEFs, indicating a specific defect in NKCC1 activity without impairment
in the Na+/K+-ATPase (Figure 5). We assayed ion transport activity under three conditions of isotonic, hypertonic, or hypotonic baths. Although both hypertonic and hypotonic low chloride baths
can stimulate NKCC1 activity in other cell types (Darman and Forbush, 2002), we did not see any

Figure 5. NGLY1 -/- MEFs show decreased NKCC1-specific ion flux. (A) Bumetanide-sensitive 86Rb flux was measured in NGLY1 +/+ and NGLY1 -/MEFs to measure NKCC1 activity. Flux was examined in three bath conditions, isotonic (iso), hypotonic (hypo), and hypertonic (hyper). There was a
significant effect of genotype (p<0.0001) in two-way ANOVA, with no significant effect of condition (p=0.5756) or interaction (p=0.8075). Adjusted
p-values for Sidak’s multiple comparisons test between NGLY1 +/+ and NGLY1 -/- are shown in the figure. (B) Ouabain-sensitive 86Rb flux was
measured in NGLY1 +/+ and NGLY1 -/- MEFs to measure Na+/K+-ATPase activity in the same three conditions as in A. There were no significant effects
of genotype (p=0.0516), condition (p=0.3047) or interaction (p=0.4711) by two-way ANOVA, indicating the NGLY1 knockout has a specific effect on
NKCC1 activity without affecting Na+/K+-ATPase activity.
The online version of this article includes the following figure supplement(s) for figure 5:
Figure supplement 1. 86Rb uptake in MEFs occurs through bumetanide-sensitive and ouabain-sensitive pathways.

Talsness, Owings, et al. eLife 2020;9:e57831. DOI: https://doi.org/10.7554/eLife.57831

10 of 22

Research article

Cell Biology Genetics and Genomics

effect of bathing medium in the MEFs, consistent with a recent report of lack of hypertonic stimulation of NKCC1 in human fibroblasts (Delpire et al., 2016). Together, these data demonstrate that
loss of NGLY1 results in a change in the glycosylation state of NKCC1 and a significant reduction in
NKCC1 function.

Discussion
Like many rare diseases, research into the pathogenesis of NGLY1 deficiency has been narrowly
focused, based on early hypotheses. This often limits how we understand the connection between a
particular disease and other pathways. For NGLY1 deficiency specifically, basic research and potential therapies have focused intensely on NRF1, the first well-established substrate of NGLY1 deglycosylation. Motivated by the extensive phenotypic variation among NGLY1 deficiency patients, we
took advantage of natural genetic variation in Drosophila to identify modifiers of NGLY1 deficiency.
This unique screen demonstrated that (1) we can model the extensive phenotypic variation observed
and (2) that genetic variation can cause this phenotypic variability. Association analysis then identified a number of exciting candidate modifier genes. Here, we have validated the novel and conserved modifier NKCC1 (Drosophila Ncc69), a new potential therapeutic target for NGLY1
deficiency.
A major advantage of screens is the identification of previously unanticipated biological connections. First, our association analysis of the lethality screen has generated a list of 61 genes that we
hope the scientific and patient communities will be able to use. Second, GSEA identified several
pathways, including rRNA metabolism and nuclear transport that are surprising based on known
NGLY1 functions. Third, ERC analysis identified genes that are coevolving with NGLY1 across the
animal kingdom, including both rRNA/ncRNA pathways and nuclear transport. It appears that rRNA
metabolism and nuclear transport are likely important to NGLY1 function, yet it remains unclear how
NGLY1 is connected to these pathways. Components of the ribosome and the nuclear pore are
often O-glycosylated. While there is no direct connection between NGLY1 and O-GlcNAcylation, we
have previously demonstrated that loss of NGLY1 impacts UDP-GlcNAc levels (Owings et al., 2018).
It is highly plausible that a misregulation of UDP-GlcNAc levels could affect O-GlcNAcylated proteins. More work is needed to determine exactly how NGLY1 is connected to these unexpected
pathways. Finally, the ERC analysis also identified 26/151 known Congenital Disorders of Glycosylation (CDG) genes. While NGLY1 is also classified as a CDG, it is unclear why there might be co-evolution with other CDG genes. Perhaps, there is a feedback mechanism, again, related to UDPGlcNAc biosynthesis that connects these genes. These results suggest that there is a previously
unknown connection between these loosely connected CDG genes.
When analyzing the list of modifier genes, it is apparent that many of the candidates are involved
in ERAD. This offers a proof-of-principle that this screen is well suited for identifying bona fide biologically relevant modifiers. Several previous studies linked NGLY1 with the ERAD process
(Bebök et al., 1998; Katiyar et al., 2005; Park et al., 2001). Yet, NGLY1 does not appear to be
required for proper ERAD function (Hirsch et al., 2003; Misaghi et al., 2004). While perturbations
to ERAD often result in ER stress, we have previously reported that there was no functional or transcriptome evidence for ER stress in a Drosophila model of NGLY1 deficiency (Owings et al., 2018).
Others have reported no ER stress in NGLY1 -/- human cells, mice, and rats (Asahina et al., 2020;
Mueller et al., 2020; Tambe et al., 2019). However, there is conflicting evidence for ER stress as it
was recently reported that ER stress markers were upregulated in NGLY -/- MEFs (Galeone et al.,
2020). Nevertheless, in our current screen, we did not identify any genes involved in canonical ER
stress responses, suggesting that ER stress might not play a large role in the pathogenesis of the disease. Here, we have reported that NKCC1 is altered in NGLY1 -/- cells, however we found that inhibiting the proteasome had no effect on the protein abundance. Thus, it may be that NGLY1 functions
to regulate proteins in various ways that are closely related to ERAD, but that do not result in direct
proteasomal degradation, and thereby, do not cause an accumulation of misfolded protein and ER
stress.
As with most hypothesis-free approaches, our analyses produced many exciting new avenues for
exploration. In order to keep our work relevant and translatable to the clinic, we have focused our
follow up experiments on genes with human orthologs. In this report we began with our top hit,
Ncc69 (human NKCC1/2), which encodes an SLC12 Na+/K+/2Cl- transporter. In cells derived from an
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NGLY1 -/- mouse model, we found that NKCC1 protein migrated at a higher average molecular
weight relative to +/+ cells. We found this altered glycosylation was accompanied by a ~ 50% reduction in NKCC1 activity.
NKCC1 contains two canonical N-linked glycosylation sites (Payne et al., 1995) similar to those
validated in NKCC2 (Paredes et al., 2006). As expected, both sites are in an extracellular loop, and
therefore, these sites face the lumen of the ER during protein translation and maturation. Because of
this arrangement, these two sites are not predicted to be accessible by NGLY1, which is localized to
the cytoplasm. However, recent work indicates that NGLY1 can deglycosylate proteins prior to their
complete retrotranslocation out of the ER (Galeone et al., 2020). NGLY1 is recruited to the cytosolic
surface of the ER where it deglycosylates BMP4, which is in fact necessary for its retrotranslocation
to the cytoplasm. Perhaps NKCC1 is being deglycosylated on one of its two canonical N-linked glycosylation sites through a similar mechanism. Alternatively, it may be that NGLY1 is acting on a noncanonical, cytoplasmic N-linked glycosylation site. Sequence analysis reveals three other asparagine
residue within the necessary N-X-S/T sequence for N-linked glycosylation, however, two are predicted to be in transmembrane domains; the third (human NKCC1 residue N168) is located in the
amino-terminal cytoplasmic tail of the protein. The recent Cryo-EM structure determined that the
amino-terminal tail is disordered and that the carboxy-terminal tail acts as a regulatory domain
(Chew et al., 2019). Although rare, there have been reports of cytosolic N-linked glycosylation,
including on the dog kidney Na+, K+-ATPase pump (reviewed in Hart et al., 2017). In all these
cases, and in our case here, the mechanism for cytoplasmic glycosylation remains unknown. Determining if one of the two canonical sites is altered or if a non-canonical, cytoplasmic site is altered is a
top priority for future work.
While we observe a glycosylation difference on NKCC1, and NGLY1 is a deglycosylating enzyme,
we cannot eliminate the possibility that this NKCC1 regulation is a secondary effect. NGLY1 may be
regulating an intermediary protein that in turn, regulates NKCC1. This was recently found to be the
case for aquaporins in NGLY1-deficient cells (Tambe et al., 2019). NGLY1 was found to regulate the
abundance of transcription factors Atf1/Creb1 independent of its enzymatic activity. Atf1/Creb1
then, in turn, regulates the transcription of several aquaporin subunits. Given that we show the abundance of NKCC1 does not change, but rather NKCC1 has a molecular weight shift, it is likely that
the altered state is due to some difference in a post-translational modification. If this effect is secondary, it may be that NGLY1 is directly affecting Golgi-localized glycosyltransferases that in turn
modify the already present glycans. Or that NGLY1 is altering the function of a sialyltransferase,
thereby altering sialic acid residues on NKCC1 which are known to cause significant changes in
migration on SDS-PAGE. This hypothesis is supported by the fact that Endo H treatment did not
affect NKCC1 from either +/+ or -/- cells, indicating that NKCC1 has been fully processed through
the Golgi. Future work to test this hypothesis could entail mass spectrometry analysis to determine
the specific glycan structures on NKCC1.
Identification of targets and modifier genes should provide insight into the pathogenesis of a disease and help explain some of the patient phenotypes. When NRF1 was identified as the first target
of NGLY1, it provided insight into some of the molecular defects observed in NGLY1-deficient cells,
including deficits in proteasomal function and expression. These cellular phenotypes, however, did
not translate well into insight into the complex patient symptoms. In contrast, decreased NKCC1
activity may explain some of the prominent features of NGLY1 deficiency. NKCC1 functions in many
secretory epithelia, such as the salivary, sweat, and lacrimal glands, to allow basolateral ion uptake
and subsequent secretion (Delpire and Gagnon, 2018). Therefore, a decrease in NKCC1 activity
could well explain the alacrima and reduced saliva and sweat production seen in NGLY1 deficiency.
Strikingly, a recent clinical report describes a patient with a homozygous deletion in NKCC1 (null)
who has many overlapping features with NGLY1 deficiency patients, including absence of saliva,
tears, and sweat (Kilquist syndrome) (Macnamara et al., 2019). The NKCC1 null mouse also displays
defects in salivation (Evans et al., 2000). Other notable, but perhaps less specific, features in the
NKCC1-deficient child, including developmental delay and gastrointestinal problems, also overlap
with those observed in NGLY1 deficiency. The NKCC1-deficient patient also had severe hearing loss,
cochlear defects, and abnormal auditory brainstem responses (ABRs). Several patients with missense
mutations in NKCC1, rather than complete loss-of-function mutations, display bilateral sensorineural
hearing loss (McNeill et al., 2020). NGLY1 deficiency patients do not have severe hearing loss, but
do report abnormal ABRs. This difference may be explained by a 50% reduction in NKCC1 activity,
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rather than complete loss of activity. The overlap in a majority of the symptoms between this new
syndrome and NGLY1 deficiency strengthens the case for both a genetic and functional connection
between NGLY1 and NKCC1.
NKCC1 may be a promising target for the development of NGLY1 deficiency therapies. Given
that it is a transporter and partially exposed to the extracellular space, NKCC1 could be particularly
amenable to modulation by small molecules. Based on our work reported here, we predict that
increasing function of NKCC1 may ameliorate some symptoms. Quercetin, a flavonoid, is a readily
available molecule that has been shown to enhance NKCC1 activity (Asano et al., 2009;
Nakajima et al., 2011). These studies demonstrated that quercetin significantly increased 86Rb
uptake in cell culture and that this increase was bumetanide-sensitive, indicating specificity to
NKCC1. This is similar to other studies showing flavonoids increasing the activity of channels, such as
the flavonoid genistein increasing activity of the cystic fibrosis transmembrane conductance regulator (CFTR) (Sugawara and Nikaido, 2014), and several flavonoids targeting cardiovascular channels
(Scholz et al., 2010). These quercetin studies, however, are in the context of normal functioning
NKCC1 protein. In our study, NKCC1 is altered from the WT state and it is unknown whether quercetin would be able to modulate the activity of an altered NKCC1. Strikingly, however, quercetin was
recently discovered in a drug screen to provide benefit to NGLY1-deficient C. elegans (Iyer et al.,
2019). These results coupled with our discovery of NKCC1 as a NGLY1 substrate offer an exciting
new avenue of treatment for NGLY1 deficiency patients. Targeted studies are needed to determine
if quercetin or other molecules could specifically enhance NKCC1 function in the context of NGLY1
deficiency.
In this study, we took a series of unbiased approaches in Drosophila to identify modifiers of
NGLY1 deficiency. This resulted in a number of new insights into the potential pathogenesis of
NGLY1 that we hope others will also investigate. With rare diseases like NGLY1 deficiency, unbiased
and forward genetic approaches are an efficient method for expanding possible avenues of investigation and therapeutic development. This study also highlights the power of using model organisms
like Drosophila to uncover pathways and genes that can be validated in mammalian systems and targeted for therapeutic development.

Materials and methods
Key resources table
Reagent type
(species) or
resource

Designation

Source or
reference

Gene
(Drosophila
melanogaster)

Pngl

GenBank

ID:35527
Dmel_CG7865

Gene
(Drosophila
melanogaster)

Ncc69

GenBank

ID: 39410
Dmel_CG4357

Gene
(Mus musculus)

NGLY1

GenBank

ID: 59007

Gene
(Mus musculus)

NKCC1

GenBank

ID: 20496

Slc12a2

Genetic
reagent
(Drosophila
melanogaster)

Pngl-RNAi

Bloomington
Drosophila
Stock Center

RRID:BDSC_54853

y1 v1; P{y+t7.7
v+t1.8=TRiP.
HMJ21590}attP40

Genetic
reagent
(Drosophila
melanogaster)

Tubulin-GAL4

Bloomington
Drosophila
Stock Center

RRID:BDSC_5138

y1 w*;
P{w+mC = tubPGAL4}LL7/TM3,
Sb1 Ser1

Genetic reagent
(Drosophila
melanogaster)

Tubulin-GAL80

Bloomington
Drosophila
Stock Center

RRID:BDSC_5190

y1 w[*];
P{w[+mC]=tubP-GAL80}LL9 P{w[+mW.hs]=FRT(w[hs])}2A/TM3, Sb1

Identifiers

Additional
information

Continued on next page
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Continued
Reagent type
(species) or
resource

Designation

Source or
reference

Genetic reagent
(Drosophila
melanogaster)

Drosophila
Genetics
Reference Panel

Bloomington
Drosophila
Stock Center

Set of 194 strains,
example strain:
BDSC:55014,
RRID:BDSC_55014

Genetic reagent
(Drosophila
melanogaster)

Pdf-GAL4

Bloomington
Drosophila
Stock Center

RRID:BDSC_6899

P{w[+mC]=PdfGAL4.P2.4}X, y1 w[*]

Genetic reagent
(Drosophila
melanogaster)

UAS-Pngl-RNAi

Bloomington
Drosophila
Stock Center

RRID:BDSC_42592

y1 sc* v1 sev21;
P{y+t7.7 v+t1.8=TRiP.
HMS02424}attP40

Genetic reagent
(Drosophila
melanogaster)

UAS-Ncc69-RNAi

Bloomington
Drosophila
Stock Center

RRID:BDSC_28682

y1 v1; P{y+t7.7
v+t1.8=TRiP.
JF03097}attP2

Cell line
(Mus musculus)

Mouse embryonic
fibroblasts (MEF)

Jackson Labs

Primary line from
mouse #027060,
https://www.jax.
org/strain/027060

Antibody

Anti-NKCC1
(Rabbit polyclonal)

Cell Signaling

Cat#14581,
RRID:AB_2798524

IB: 1:1000

Antibody

Anti-TCF11/NRF1
(Rabbit
monoclonal)

Cell Signaling

Cat#8052,
RRID:AB_11178947

IB: 1:1000

Antibody

IRDye 800CW
Goat-anti-rabbit

Abcam

Cat#216773

IB: 1:10,000

Commercial
assay or kit

Cell Fractionation
Kit

Cell Signaling

Cat#9038

Chemical
compound,
drug

Bortezomib

EMD Millipore

Cat# 179324-69-7

Software,
algorithm

Genome Wide
Association

Chow et al., 2016

Software,
algorithm

Gene Set
Enrichment
Analysis

Subramanian
et al., 2005

Software,
algorithm

Evolution
Rate Covariation

Clark et al., 2012

Software,
algorithm

R

https://www.
r-project.org/

Identifiers

Additional
information

Drosophila lines
Flies were maintained at 25˚C on a 12 hr light/dark cycle and raised on a standard diet based on the
Bloomington Stock Center standard medium with malt. All flies were aged 3–5 days old for experiments. For the DGRP screen, the following D. melanogaster stocks were used: PnglRNAi (Bloomington Drosophila Stock Center: 54853) and Tubulin-GAL4 driver (5138). The Tubulin-GAL80 strain was
provided by Dr. Carl Thummel (University of Utah). The DGRP strains are available at the Bloomington Drosophila Stock Center. To measure circadian rhythm, the following stocks were used: a w- Berlin control strain, a w; Pdf-GAL4 strain (outcrossed to w- Berlin), and a yv; UAS-PnglRNAi strain
(Bloomington stock center #42592). For bang sensitivity assays, the following stocks were used:
UAS-PnglRNAi (BL #54853), UAS-Ncc69RNAi (BL #28682), and repo-GAL4. These stocks were obtained
from the Bloomington Stock Center and Adrian Rothenfluh (University of Utah) respectively.

DGRP screen
Virgin females from the DGRP strains were fed yeast overnight and then crossed with males from
the donor strain UAS-PnglRNAi/Cyo,Tubulin-GAL80; Tubulin-GAL4/TM3,Sb in two replicate bottles.
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Progeny were collected and scored for the four balancer classes: CyO, Sb, double balanced, or no
balancers, with the no balancer flies being the NGLY1 KD. This cross should produce the expected
1:1:1:1 ratio of the four genotypes. Given that there is always a very low level of lethality associated
with each balancer, the largest balancer class was considered the closest to the expected number.
We scored at least 200 flies per DGRP cross. Males and females were combined for a single count.
To calculate the proportion of NGLY1 KD flies by generating a ratio of NGLY1 knockdown/largest
balancer class. This metric was used for the GWA.

Genome wide association
GWA was performed as previously described (Chow et al., 2016). DGRP genotypes were downloaded from the website, http://dgrp.gnets.ncsu.edu/. Variants were filtered for minor allele frequency (0.05), and non-biallelic sites were removed. A total of 2,007,145 variants were included in
the analysis. The proportion of NGLY1 KD flies surviving was regressed on each SNP. To account for
cryptic relatedness (He et al., 2014; Huang et al., 2014), GEMMA (v. 0.94) (Zhou and Stephens,
2012) was used to both estimate a centered genetic relatedness matrix and perform association
tests using the following linear mixed model (LMM):
y ¼ a þ xb þ u þ 
u ~ MVN nð0; lt ^ ð 1ÞKÞ
" ~ MVN nð0; t ^ ð 1ÞI nÞ
where, as described and adapted from Zhou and Stephens, 2012, y is the n-vector of proportion
lethality for the n lines, a is the intercept, x is the n-vector of marker genotypes, b is the effect size
of the marker. u is a n x n matrix of random effects with a multivariate normal distribution (MVN_n)
that depends on l, the ratio between the two variance components, t^( 1), the variance of residuals
errors, and where the covariance matrix is informed by K, the calculated n x n marker-based relatedness matrix. K accounts for all pairwise non-random sharing of genetic material among lines. e, is a
n-vector of residual errors, with a multivariate normal distribution that depends on t^( 1) and I_n, the
identity matrix. Genes were identified from SNP coordinates using the BDGP R54/dm3 genome
build. An SNP was assigned to a gene if it was +/- 1 kb from a gene body.

Gene set enrichment analysis
GSEA was run to generate a rank-list of genes based on their enrichment for significantly associated
polymorphisms as previously described (Palu et al., 2019). Polymorphisms within 1 kb of more than
one gene were assigned to one gene based on a priority list of exon, UTR, intron, and upstream or
downstream. Genes were assigned to GO categories, and calculation of enrichment score was performed as described (Subramanian et al., 2005). Only gene sets with 5 genes,>0.25 enrichment
score, and a p<0.05 were considered.

Evolutionary rate covariation
ERC is a method to examine the similarity of evolutionary histories of pairs of genes (Clark et al.,
2012). The method examines the variation over time of a gene’s rate of sequence evolution. Using
estimates of evolutionary rate over the branches of a gene’s phylogenetic tree, the method measures the correlation between genes of these branch-specific rates. Genes within correlated rate variation tend to be functionally related and have been used to discover new genes within pathways
and diseases (Brunette et al., 2019; Priedigkeit et al., 2015; Raza et al., 2019).
ERC values in this study were taken from a compilation of ERC correlations calculated separately
for three taxonomic groups: 62 mammals, 39 non-mammalian vertebrates, and 22 Drosophila species. Mammal and non-mammalian vertebrate alignments were taken from the multiz alignment
available from the UCSC Genome Browser (Haeussler et al., 2019). For each alignment, we filtered
out low-quality orthologs containing fewer than 50 non-gap amino acid sites or less than 70% nongap sites and removed alignments with fewer than 15 species. Alignments were made for the Drosophila species after downloading protein-coding genome sequences from FlyBase and NCBI.
Orthologous groups were identified using Orthofinder and alignments made with PRANK
(Emms and Kelly, 2015; Löytynoja and Goldman, 2008). For each amino acid alignment, we estimated branch lengths using aaml in the phylogenetic analysis using maximum likelihood (PAML)
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package (Yang, 2007). ERC values (correlation coefficients) for all genes with NGLY1 were calculated
using the RERconverge package (Kowalczyk et al., 2019). We report the ERC results for the mammalian group as the negative log of their p-values for each gene pair (Supplementary file 5
‘nlogpvbest1’). Each gene pair also incorporated results from the vertebrate and Drosophila datasets
by summing their negative log p-values, when orthologs were present for their respective datasets
(Supplementary file 5 ‘sumnlogpvbest’). The resulting taxonomically integrated results of ERC with
NGLY1 were sorted and used for gene set enrichment analysis (GSEA).

Drosophila circadian rhythm assay
Male flies with the following genotypes were used in circadian rhythm assays: w/Y;Pdf-GAL4/+, yv/Y;
UAS-PnglRNAi/+, and yv/Y; Pdf-GAL4/UAS-PnglRNAi/+. Two- to 5-day-old flies were entrained for at
least 3 days to a 12 hr light: 12 hr dark regimen (LD) within a Drosophila Activity Monitor (DAM; TriKinetics, Waltham, MA) filled with standard fly food. After entrainment, flies were monitored in complete darkness (DD) for 8 days. The data was collected in 30 min bins, and analyzed for period
length using ClockLab, Version 6. Graphs were generated and one-way ANOVA performed, with
Tukey’s multiple comparison of all three genotypes, using GraphPad Prism, Version 8.

Drosophila seizure assay
The Bang Sensitivity Assay (BSA) was performed on the following genotypes: UAS-PnglRNAi; repoGAL4, UAS-Ncc69RNAi; repo-GAL4, and UAS-PnglRNAi/+; UAS-Ncc69RNAi/repo-GAL4. Females 4–7
days old were assayed. Flies were not exposed to CO2 for 3 days prior to BSA testing. Flies were
flipped into empty vials and allowed to rest for 2 hr. They were then vortexed on a Thermo Scientific
LP Vortex Mixer for 10 s at maximum speed. The vortexed flies were filmed for 60 s. The video was
used to score seizures at 5, 10, 30, and 60 s.

Mammalian cell culture and proteasome inhibition
MEFs were generated by Jackson Laboratory (Bar Harbor, Maine) from NGLY1 knockout mice and
littermate controls (C57BL/6J-Ngly1em4Lutzy/J, #027060). MEFs were immortalized in the laboratory
of Dr. Hamed Jafar-Nejad (Baylor College of Medicine) and then gifted to us. MEFs were grown in
DMEM (Gibco 11965) supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin
in 5% CO2 at 37˚C. For proteasome inhibition, MEFs were incubated with 500 nM bortezomib (EMD
Millipore) or an equivalent volume of DMSO as a vehicle control, for 4 hr under standard conditions.

Western blotting
MEFs were grown to 80–90% confluency then collected. Cell pellets were weighed and then resuspended in a proportional volume of phosphate buffered saline (PBS). Equivalent volumes of resuspension were always used for each lysis. Cells were lysed using a cell fractionation kit (Cell Signaling
Technologies, #9038) with each buffer supplemented with 1 mM PMSF and 1x protease inhibitor
cocktail (Cell Signaling Technologies, #5871).
Lysates were separated by SDS-PAGE on 3–8% Tris-acetate gels (BioRad #3450129) for 2.5 hr at
150V, then transferred to PVDF membrane by wet transfer at 50V for 1 hr. Membranes were blocked
in either 5% milk or 5% BSA according to the recommendations of the primary antibody manufacturer. Primary antibodies were as follows: anti-NKCC1 (Cell Signaling Technologies #14581), antiTCF11/NRF1 (Cell Signaling Technologies #8052). Membranes were incubated in primary antibody
at 1:1000 in blocking buffer overnight. IRDye secondary antibody (Abcam #216773) was used for
infrared detection at 1:10,000 dilution in blocking buffer for 1 hr. Membranes were scanned on an
Odyssey CLx (Li-cor) and analyzed with the accompanying software, Image Studio.

Deglycosylation reactions
MEFs were lysed in the same manner as described for western blotting. The membrane fraction was
then incubated with one of the three deglycosylation enzymes: O-Glycosidase (New England Biolabs, #P0733), PNGase F (New England Biolabs, #P0704), Endoglycosidase F (New England Biolabs,
#P0702) according to the manufacturer’s directions. Reactions were incubated at 37˚C for 1 hr. Controls were treated with all the same buffers and reaction conditions but without the added enzyme.
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Rb+ flux assay
20,000 cells/well of immortalized MEFs from control or Ngly1 -/- mice were seeded into a 96-well
plate. The following day, media was removed and the cells were washed with 1x PBS. Of pre-incubation medium (in mM, 135 Na gluconate, 5 K gluconate, 1 Ca gluconate, 1 Mg gluconate, 15 HEPES
pH 7.4, 5 glucose), 100 ml was added to each well and the cells were incubated for 30 min at 37˚C.
Next, 100 ml of pre-incubation medium containing either DMSO, bumetanide, or ouabain was added
to each well to achieve final concentrations of 0.1% (DMSO), 10 mM (bumetanide), or 0.1 mM (ouabain) and incubated for 30 min at room temperature. Then, 150 mL of medium containing DMSO
(0.1%), bumetanide (10 mM) or ouabain (0.1 mM), as well as 86Rb (10 mCi/ml), was added to each
well. Three different media were used. Isotonic media contained (in mM): 140 NaCl, 5 KCl, 2 CaCl2,
1 MgCl2, 5 glucose, 15 HEPES pH 7.4. Hypertonic medium was the same as isotonic medium, with
the addition of 75 mM sucrose. For hypotonic medium, isotonic medium was diluted 1:2 in water.
The cells were incubated for 7 min at room temperature. Medium was removed and the cells were
washed three times with ice-cold 1x PBS. Cells were lysed in 100 ml 2% SDS and incubated for 15
min at room temperature. Radioactivity was measured in a liquid scintillation counter.
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He BZ, Ludwig MZ, Dickerson DA, Barse L, Arun B, Vilhjálmsson BJ, Jiang P, Park SY, Tamarina NA, Selleck SB,
Wittkopp PJ, Bell GI, Kreitman M. 2014. Effect of genetic variation in a Drosophila model of diabetesassociated misfolded human proinsulin. Genetics 196:557–567. DOI: https://doi.org/10.1534/genetics.113.
157800, PMID: 24281155
He P, Grotzke JE, Ng BG, Gunel M, Jafar-Nejad H, Cresswell P, Enns GM, Freeze HH. 2015. A congenital
disorder of deglycosylation: biochemical characterization of N-glycanase 1 deficiency in patient fibroblasts.
Glycobiology 25:836–844. DOI: https://doi.org/10.1093/glycob/cwv024, PMID: 25900930
Hirsch C, Blom D, Ploegh HL. 2003. A role for N-glycanase in the cytosolic turnover of glycoproteins. The EMBO
Journal 22:1036–1046. DOI: https://doi.org/10.1093/emboj/cdg107, PMID: 12606569

Talsness, Owings, et al. eLife 2020;9:e57831. DOI: https://doi.org/10.7554/eLife.57831

19 of 22

Research article

Cell Biology Genetics and Genomics
Hosomi A, Fujita M, Tomioka A, Kaji H, Suzuki T. 2016. Identification of PNGase-dependent ERAD substrates in
Saccharomyces cerevisiae. Biochemical Journal 473:3001–3012. DOI: https://doi.org/10.1042/BCJ20160453
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Paredes A, Plata C, Rivera M, Moreno E, Vázquez N, Muñoz-Clares R, Hebert SC, Gamba G. 2006. Activity of the
renal na+-K+-2Cl- cotransporter is reduced by mutagenesis of N-glycosylation sites: role for protein surface
charge in cl- transport. American Journal of Physiology. Renal Physiology 290:F1094–F1102. DOI: https://doi.
org/10.1152/ajprenal.00071.2005, PMID: 16291577
Park H, Suzuki T, Lennarz WJ. 2001. Identification of proteins that interact with mammalian peptide:n-glycanase
and implicate this hydrolase in the proteasome-dependent pathway for protein degradation. PNAS 98:11163–
11168. DOI: https://doi.org/10.1073/pnas.201393498, PMID: 11562482
Payne JA, Xu JC, Haas M, Lytle CY, Ward D, Forbush B. 1995. Primary structure, functional expression, and
chromosomal localization of the bumetanide-sensitive Na-K-Cl cotransporter in human Colon. Journal of
Biological Chemistry 270:17977–17985. DOI: https://doi.org/10.1074/jbc.270.30.17977, PMID: 7629105
Priedigkeit N, Wolfe N, Clark NL. 2015. Evolutionary signatures amongst disease genes permit novel methods
for gene prioritization and construction of informative gene-based networks. PLOS Genetics 11:e1004967.
DOI: https://doi.org/10.1371/journal.pgen.1004967, PMID: 25679399
Qi L, Tsai B, Arvan P. 2017. New insights into the physiological role of endoplasmic Reticulum-Associated
degradation. Trends in Cell Biology 27:430–440. DOI: https://doi.org/10.1016/j.tcb.2016.12.002, PMID: 2
8131647
Raza Q, Choi JY, Li Y, O’Dowd RM, Watkins SC, Chikina M, Hong Y, Clark NL, Kwiatkowski AV. 2019.
Evolutionary rate covariation analysis of E-cadherin identifies raskol as a regulator of cell adhesion and actin
dynamics in Drosophila. PLOS Genetics 15:e1007720. DOI: https://doi.org/10.1371/journal.pgen.1007720,
PMID: 30763317
Renn SC, Park JH, Rosbash M, Hall JC, Taghert PH. 1999. A pdf neuropeptide gene mutation and ablation of
PDF neurons each cause severe abnormalities of behavioral circadian rhythms in Drosophila. Cell 99:791–802.
DOI: https://doi.org/10.1016/S0092-8674(00)81676-1, PMID: 10619432
Rusan ZM, Kingsford OA, Tanouye MA. 2014. Modeling glial contributions to seizures and epileptogenesis:
cation-chloride cotransporters in Drosophila melanogaster. PLOS ONE 9:e101117. DOI: https://doi.org/10.
1371/journal.pone.0101117, PMID: 24971529
Scholz EP, Zitron E, Katus HA, Karle CA. 2010. Cardiovascular ion channels as a molecular target of flavonoids.
Cardiovascular Therapeutics 28:e46–e52. DOI: https://doi.org/10.1111/j.1755-5922.2010.00212.x,
PMID: 20633021
Simon DB, Lifton RP. 1996. The molecular basis of inherited hypokalemic alkalosis: bartter’s and Gitelman’s
syndromes. American Journal of Physiology-Renal Physiology 271:F961–F966. DOI: https://doi.org/10.1152/
ajprenal.1996.271.5.F961, PMID: 8945989
Singh R, Almutairi MM, Pacheco-Andrade R, Almiahuob MY, Di Fulvio M. 2015. Impact of hybrid and complex
N-Glycans on cell surface targeting of the endogenous chloride cotransporter Slc12a2. International Journal of
Cell Biology 2015:1–20. DOI: https://doi.org/10.1155/2015/505294
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR,
Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. PNAS 102:15545–15550. DOI: https://doi.org/10.1073/pnas.0506580102,
PMID: 16199517
Sugawara E, Nikaido H. 2014. Properties of AdeABC and AdeIJK efflux systems of Acinetobacter baumannii
compared with those of the AcrAB-TolC system of Escherichia coli. Antimicrobial Agents and Chemotherapy
58:7250–7257. DOI: https://doi.org/10.1128/AAC.03728-14
Tambe MA, Ng BG, Freeze HH. 2019. N-Glycanase 1 transcriptionally regulates aquaporins independent of its
enzymatic activity. Cell Reports 29:4620–4631. DOI: https://doi.org/10.1016/j.celrep.2019.11.097, PMID: 31
875565
Tomlin FM, Gerling-Driessen UIM, Liu YC, Flynn RA, Vangala JR, Lentz CS, Clauder-Muenster S, Jakob P, Mueller
WF, Ordoñez-Rueda D, Paulsen M, Matsui N, Foley D, Rafalko A, Suzuki T, Bogyo M, Steinmetz LM,
Radhakrishnan SK, Bertozzi CR. 2017. Inhibition of NGLY1 inactivates the transcription factor Nrf1 and

Talsness, Owings, et al. eLife 2020;9:e57831. DOI: https://doi.org/10.7554/eLife.57831

21 of 22

Research article

Cell Biology Genetics and Genomics
potentiates proteasome inhibitor cytotoxicity. ACS Central Science 3:1143–1155. DOI: https://doi.org/10.1021/
acscentsci.7b00224, PMID: 29202016
Wolfe NW, Clark NL. 2015. ERC analysis: web-based inference of gene function via evolutionary rate covariation.
Bioinformatics 31:3835–3837. DOI: https://doi.org/10.1093/bioinformatics/btv454, PMID: 26243019
Yang Z. 2007. PAML 4: phylogenetic analysis by maximum likelihood. Molecular Biology and Evolution 24:1586–
1591. DOI: https://doi.org/10.1093/molbev/msm088, PMID: 17483113
Zhou X, Stephens M. 2012. Genome-wide efficient mixed-model analysis for association studies. Nature Genetics
44:821–824. DOI: https://doi.org/10.1038/ng.2310, PMID: 22706312
Zhu B, Jiang L, Huang T, Zhao Y, Liu T, Zhong Y, Li X, Campos A, Pomeroy K, Masliah E, Zhang D, Xu H. 2017.
ER-associated degradation regulates alzheimer’s amyloid pathology and memory function by modulating gsecretase activity. Nature Communications 8:1472. DOI: https://doi.org/10.1038/s41467-017-01799-4, PMID: 2
9133892
Zolekar A, Lin VJT, Mishra NM, Ho YY, Hayatshahi HS, Parab A, Sampat R, Liao X, Hoffmann P, Liu J, Emmitte
KA, Wang YC. 2018. Stress and interferon signalling-mediated apoptosis contributes to pleiotropic anticancer
responses induced by targeting NGLY1. British Journal of Cancer 119:1538–1551. DOI: https://doi.org/10.
1038/s41416-018-0265-9, PMID: 30385822

Talsness, Owings, et al. eLife 2020;9:e57831. DOI: https://doi.org/10.7554/eLife.57831

22 of 22

